JP7594004B2 - フェロポーチン阻害剤(vit-2763)を用いる鎌状赤血球症を治療するための方法及び組成物 - Google Patents

フェロポーチン阻害剤(vit-2763)を用いる鎌状赤血球症を治療するための方法及び組成物 Download PDF

Info

Publication number
JP7594004B2
JP7594004B2 JP2022523485A JP2022523485A JP7594004B2 JP 7594004 B2 JP7594004 B2 JP 7594004B2 JP 2022523485 A JP2022523485 A JP 2022523485A JP 2022523485 A JP2022523485 A JP 2022523485A JP 7594004 B2 JP7594004 B2 JP 7594004B2
Authority
JP
Japan
Prior art keywords
compound
group
scd
treatment
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022523485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500060A (ja
JP2023500060A5 (cg-RX-API-DMAC7.html
Inventor
マノロヴァ,ヴァニア
デュレンベルガー,フランツ
ニッフェネガー,ナジャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vifor International AG
Original Assignee
Vifor International AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor International AG filed Critical Vifor International AG
Publication of JP2023500060A publication Critical patent/JP2023500060A/ja
Publication of JP2023500060A5 publication Critical patent/JP2023500060A5/ja
Application granted granted Critical
Publication of JP7594004B2 publication Critical patent/JP7594004B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
JP2022523485A 2019-10-22 2020-10-22 フェロポーチン阻害剤(vit-2763)を用いる鎌状赤血球症を治療するための方法及び組成物 Active JP7594004B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962924556P 2019-10-22 2019-10-22
EP19000483 2019-10-22
US62/924,556 2019-10-22
EP19000483.8 2019-10-22
EP20163777 2020-03-17
EP20163777.4 2020-03-17
EP20176336.4 2020-05-25
EP20176336 2020-05-25
PCT/EP2020/079802 WO2021078889A1 (en) 2019-10-22 2020-10-22 Methods and compositions for treating sickle cell disease with a ferroportin inhibitor (vit-2763)

Publications (3)

Publication Number Publication Date
JP2023500060A JP2023500060A (ja) 2023-01-04
JP2023500060A5 JP2023500060A5 (cg-RX-API-DMAC7.html) 2023-06-06
JP7594004B2 true JP7594004B2 (ja) 2024-12-03

Family

ID=73005635

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523485A Active JP7594004B2 (ja) 2019-10-22 2020-10-22 フェロポーチン阻害剤(vit-2763)を用いる鎌状赤血球症を治療するための方法及び組成物

Country Status (11)

Country Link
US (1) US20220274973A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048262A1 (cg-RX-API-DMAC7.html)
JP (1) JP7594004B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220086563A (cg-RX-API-DMAC7.html)
CN (1) CN114765955B (cg-RX-API-DMAC7.html)
AU (1) AU2020369137A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007616A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154524A1 (cg-RX-API-DMAC7.html)
IL (1) IL291137A (cg-RX-API-DMAC7.html)
MX (1) MX2022004806A (cg-RX-API-DMAC7.html)
WO (1) WO2021078889A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4536683A4 (en) * 2022-06-07 2026-06-10 Protagonist Therapeutics Inc HEPCIDINE MIMETIC AGENTS FOR THE TREATMENT OF SICKLE CELL DISEASE
WO2024083980A1 (en) 2022-10-21 2024-04-25 Vifor (International) Ag Bicyclic ferroportin inhibitors
CN121511085A (zh) 2023-06-26 2026-02-10 威佛(国际)股份公司 用于遗传性血色素沉着病(hh)的治疗的膜铁转运蛋白抑制剂
WO2026041650A1 (en) 2024-08-20 2026-02-26 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of lupus nephritis
WO2026120152A1 (en) 2024-12-06 2026-06-11 Vifor (International) Ag Prolonged-release dosage forms of ferroportin inhibitors for use in treating hereditary haemochromatosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018192973A1 (en) 2017-04-18 2018-10-25 Vifor (International) Ag Ferroportin-inhibitor salts

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068089A2 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
US11191818B2 (en) * 2016-08-04 2021-12-07 Takeda Pharmaceutical Company Limited Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
ES2934492T3 (es) 2018-12-13 2023-02-22 Global Blood Therapeutics Inc Inhibidores de ferroportina y métodos de uso

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018192973A1 (en) 2017-04-18 2018-10-25 Vifor (International) Ag Ferroportin-inhibitor salts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MANOLOVA Vania, et al.,The oral ferroportin inhibitor VIT-2763 prevents hemolysis and vaso-occlusion in a sickle cell diseases model II,LIPPINCOTT WILLIAMS AND WILKINS NLD,2020年06月12日,vol. 4, no. Supplement 1

Also Published As

Publication number Publication date
US20220274973A1 (en) 2022-09-01
AU2020369137A1 (en) 2022-04-07
BR112022007616A2 (pt) 2022-07-12
JP2023500060A (ja) 2023-01-04
IL291137A (en) 2022-05-01
KR20220086563A (ko) 2022-06-23
CN114765955A (zh) 2022-07-19
CA3154524A1 (en) 2021-04-21
EP4048262A1 (en) 2022-08-31
MX2022004806A (es) 2022-05-16
WO2021078889A1 (en) 2021-04-29
CN114765955B (zh) 2025-06-24

Similar Documents

Publication Publication Date Title
CN114765955B (zh) 用铁转运蛋白抑制剂(vit-2763)治疗镰状细胞病的方法和组合物
JP7554253B2 (ja) 輸血依存性β-サラセミア(TDT)の治療で使用するためのフェロポーチン阻害剤
JP7561180B2 (ja) 腎臓損傷の予防及び治療で使用するためのフェロポーチン阻害剤
KR20230134476A (ko) 골수이형성 증후군(mds)의 치료에 사용하기 위한 페로포틴-억제제
Gotardo et al. Targeting P-selectin and interleukin-1b in mice with sickle cell disease: effects on vaso-occlusion, liver injury and organ iron deposition
US20140350097A1 (en) Treatment of hypotension associated with hemodialysis
EA048997B1 (ru) Способы и композиции для лечения серповидно-клеточной болезни ингибитором ферропортина (vit-2763)
KR20260028017A (ko) 유전성 혈색소침착증(hh)의 치료에 사용하기 위한 페로포틴-저해제
CA2650433A1 (en) Method of treatment of hereditary hemochromatosis
CN116710091A (zh) 用于治疗骨髓增生异常综合征(mds)的膜铁转运蛋白抑制剂
EA049341B1 (ru) Применение ингибиторов ферропортина для лечения миелодиспластических синдромов (мдс)
EA048075B1 (ru) Ингибиторы ферропортина для применения при лечении трансфузионно-зависимой бета-талассемии (tdt)
EA047958B1 (ru) Ингибиторы ферропортина для применения с целью предупреждения и лечения повреждений почек

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240903

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241121

R150 Certificate of patent or registration of utility model

Ref document number: 7594004

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150